Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature

References

• Horny HP, Metcalfe DD, and Akin C, et al. Mastocytosis. In: Swerdlow SH, Campo, E, and Harris, NL, et al., editors. WHO classification of tumors of hematopoietic and lymphoid tissues. Lyon (France): International Agency for Research and Cancer (IARC); 2017. 62–69.
   Google Scholar
• Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727–5736.
   PubMed Web of Science ®Google Scholar
• Pieri L, Bonadonna P, Elena C, et al. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. Am J Hematol. 2016;91(7):692–699.
   PubMed Web of Science ®Google Scholar
• Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57(6):604–608.
   PubMed Web of Science ®Google Scholar
• Wang SA, Hutchinson L, Tang G, et al. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. 2013;88(3):219–224.
   PubMed Web of Science ®Google Scholar
• Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med. 2005;129(2):219–222.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo clinic patients and current literature. Curr Opin Hematol. 2010Mar;17(2):125–132. PMID: 20075725.
   PubMed Web of Science ®Google Scholar
• Reiter A, George TI, Gotlib J. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Blood. 2020 Apr 16;135(16):1365–1376.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470–478.
   PubMed Web of Science ®Google Scholar
• Kurian CJ, Madhavan I, Krishnankutty PK, et al. Compressive myelopathy caused by isolated epidural myeloid sarcoma with systemic mastocytosis. Rare presentation of a hematological malignancy. Neuro-sciences (Riyadh). 2014;19. 238–239.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang L, Zhou D, et al. A case report on concurrent occurrence of systemic mastocytosis and myeloid sarcoma presenting with extensive skin involvements and the results of genetic study. Medicine (Baltimore). 2020 Dec 11;99(50):e21948.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Ascani S, Cox MC, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007 Feb;21(2):340–350.
   PubMed Web of Science ®Google Scholar
• Goyal G, Bartley AC, Patnaik MM, et al. Clinical features and outcomes of extrame- dullary myeloid sarcoma in the United States: analysis using a national data set. Blood Cancer J. 2017;7(8):e592.
   PubMedGoogle Scholar
• Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366–2372.
   PubMed Web of Science ®Google Scholar
• Damaj G, Joris M, Chandesris O, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014 Jan;9(1):e85362.
   PubMed Web of Science ®Google Scholar
• Sotlar K, Colak S, Bache A, et al. Variable presence of KIT D816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220(5):586–595.
   PubMed Web of Science ®Google Scholar
• Zappulla JP, Dubreuil P, Desbois S, et al. Mastocytosis in mice expressing human kit receptor with the activating Asp816Val mutation. J Exp Med. 2005;202(12):1635–1641.
   PubMed Web of Science ®Google Scholar
• Gerbaulet A, Wickenhauser C, Scholten J, et al. Mast cell hyperplasia, B cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood. 2011;117(6):2012–2021.
   PubMed Web of Science ®Google Scholar
• Jawhar M, Schwaab J, Schnittger S, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015 May;29(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Schwaab J, Schnittger S, Sotlar K, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460–2466.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho T, Elala Y, et al. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol. 2016;91(9):888–893.
   PubMed Web of Science ®Google Scholar
• Jawhar M, Schwaab J, Schnittger S, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis. Leukemia. 2016;30(1):136–143.
   PubMed Web of Science ®Google Scholar
• Jawhar M, Schwaab J, Naumann N, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137–145.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Reichard KK, et al. World Health Organization class-independent risk categorization in mastocytosis. Blood Cancer J. 2019;9(3):29.
   PubMedGoogle Scholar
• Jawhar M, Schwaab J, Alvarez-Twose I, et al. Mars: mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol. 2019;37(31):2846–2856.
   PubMed Web of Science ®Google Scholar
• Pastoret C, Houot R, Llamas-Gutierrez F, et al. Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing. Leuk Lymphoma. 2017 Apr;58(4):1008–1012.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011 Feb 24;117(8):2348–2357.
   PubMed Web of Science ®Google Scholar
• Naumann N, Jawhar M, Schwaab J, et al. Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis. Genes Chromosomes Cancer. 2018 May;57(5):252–259.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Gundry MC, Goodell MA. DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a030320.
   PubMed Web of Science ®Google Scholar
• Sato H, Wheat JC, Steidl U, et al. DNMT3A and TET2 in the pre-leukemic phase of hematopoietic disorders. Front Oncol. 2016 Aug 22;6:187.
   PubMed Web of Science ®Google Scholar
• Worobec AS, Akin C, Scott LM, et al. Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the pathogenesis of mastocytosis. J Allergy Clin Immunol. 1998;102(3):523–524.
   PubMed Web of Science ®Google Scholar
• Shah S, Pardanani A, Elala YC, et al. Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases. Am J Hematol. 2018 Dec;93(12):1461–1466.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Pozdnyakova O, Stachurski D, Hutchinson L, et al. Trisomy 8 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2008 May;183(1):49–52.
   PubMedGoogle Scholar
• Boyer J. del(13q) in myeloid malignancies. Atlas Genet Cytogenet Oncol Haematol. 2002;6 31–33 .
   Google Scholar
• Zhou Y, Tang G, Medeiros LJ, et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012 Feb;25(2):237–245.
   PubMed Web of Science ®Google Scholar
• Hou JZ, Ye JC, Pu JJ, et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14(1):66.
   PubMed Web of Science ®Google Scholar
• Nicolosi M, Patriarca A, Andorno A, et al. Precision medicine in systemic mastocytosis. Medicina (Kaunas). 2021 Oct 20;57(11):1135.
   PubMed Web of Science ®Google Scholar